Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
March 14 2024 - 4:26PM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company),
a clinical-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
severe monogenic diseases of the central nervous system (CNS),
today announced that it will report its financial results for the
full-year ended December 31, 2023, provide corporate and clinical
updates and host a corporate update conference call on Tuesday,
March 19, 2024, at 4:30 PM Eastern Time.
Conference Call
Details |
Tuesday, March 19,
at 4:30 PM Eastern Time / 3:30 PM Central
Time |
Toll Free: 877-407-0792 |
International:
201-689-8263 |
Conference ID: 13744574 |
Webcast:
https://ir.tayshagtx.com/news-events/events-presentations |
|
About Taysha Gene TherapiesTaysha Gene
Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company
focused on advancing adeno-associated virus (AAV)-based gene
therapies for severe monogenic diseases of the central nervous
system. Its lead clinical program TSHA-102 is in development for
Rett syndrome, a rare neurodevelopmental disorder with no approved
disease-modifying therapies that address the genetic root cause of
the disease. With a singular focus on developing
transformative medicines, Taysha aims to address severe unmet
medical needs and dramatically improve the lives of patients and
their caregivers. The Company’s management team has proven
experience in gene therapy development and commercialization.
Taysha leverages this experience, its manufacturing process and a
clinically and commercially proven AAV9 capsid in an effort to
rapidly translate treatments from bench to bedside. For more
information, please visit www.tayshagtx.com.
Company Contact:Hayleigh Collins Director, Head
of Corporate Communications, and Investor RelationsTaysha Gene
Therapies, Inc.hcollins@tayshagtx.com
Media Contact:Carolyn HawleyInizio
EvokeCarolyn.hawley@inizioevoke.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Aug 2023 to Aug 2024